WO2021175186A1 - Utilisation d'un peptide court à petites molécules dans la préparation d'un produit destiné à traiter l'acné - Google Patents

Utilisation d'un peptide court à petites molécules dans la préparation d'un produit destiné à traiter l'acné Download PDF

Info

Publication number
WO2021175186A1
WO2021175186A1 PCT/CN2021/078441 CN2021078441W WO2021175186A1 WO 2021175186 A1 WO2021175186 A1 WO 2021175186A1 CN 2021078441 W CN2021078441 W CN 2021078441W WO 2021175186 A1 WO2021175186 A1 WO 2021175186A1
Authority
WO
WIPO (PCT)
Prior art keywords
short peptide
small molecule
acne
product
molecule short
Prior art date
Application number
PCT/CN2021/078441
Other languages
English (en)
Chinese (zh)
Inventor
陈小佳
洪岸
苏梓坚
Original Assignee
暨南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 暨南大学 filed Critical 暨南大学
Publication of WO2021175186A1 publication Critical patent/WO2021175186A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • certain drugs can also cause acne by stimulating the sebaceous glands, especially corticosteroids and anabolic steroids.
  • the formation of "rosacea" on the face is caused by the use of skin care products containing bad additives.
  • acne does not affect normal movement, because it occurs mostly on the face, it has a great impact on the patient's psychology and social life.
  • keratinocytes and sebum gradually accumulate to form acne.
  • Acne is an early symptom of acne. Because swollen acne damages the hair follicle wall, sebum and microorganisms can easily penetrate the hair follicle wall and cause neutrophil and T cell inflammation.
  • topical all-trans retinoic acid, adapalene and tazarotene are the first choice drugs for the treatment of mild acne; oral retinoic acid drugs are mainly used for severe acne, which can promote the renewal of epidermal cells and change the abnormal filtration.
  • Foam keratinization and promote acne dissolution by regulating the proliferation and differentiation of epidermal cells, stimulate the formation of new collagen and the proliferation of fibroblasts and reduce inflammation (BALDWIN H E, NIGHLAND M, KENDALL C, et al.
  • the said products are medical products, skin care products or cosmetics; preferably medical products, including medicines and the like.
  • the seaweed polysaccharide hydrogel is preferably obtained by the following method: adding seaweed polysaccharide powder to water and mixing uniformly to obtain the seaweed polysaccharide hydrogel.
  • the content of seaweed polysaccharide in the seaweed polysaccharide hydrogel is preferably 10% (w/w).
  • Figure 1 is a graph showing the results of a clone formation experiment to determine the proliferation inhibitory effects of short peptides on human keratinocytes (HACAT), human skin fibroblasts (HSF) and human sebocytes (SZ95).
  • HACAT human keratinocytes
  • HSF human skin fibroblasts
  • SZ95 human sebocytes
  • Figure 3 is the result of oil red O staining method to determine the oil secretion of human sebaceous gland cells (SZ95); wherein, A is the DHT control; B is the co-culture of DHT and short peptides.
  • CCK-8 method detects the growth inhibitory effect of short peptides on human keratinocytes (HACAT), human skin fibroblasts (HSF) and human sebocytes (SZ95)
  • the short peptide can inhibit the growth of human keratinocytes (HACAT), human skin fibroblasts (HSF) and human sebaceous gland cells (SZ95), and its toxicity is weak, and it inhibits proliferation at high concentrations. The capacity is only reduced by about 20%. It shows that the short peptide is less toxic to skin-derived cells.
  • HACAT human keratinocytes
  • HSF human skin fibroblasts
  • SZ95 human sebaceous gland cells
  • a certain amount of sebaceous gland cells SZ95 were seeded in a 6-well plate (1.2 ⁇ 10 6 cells/well), and different concentrations of short peptides (20 ⁇ M, 100 ⁇ M and 200 ⁇ M) were added to the wells the next day, and no short peptide was added as a blank. Control, incubate for 48 hours and wash with PBS. Collect the cells in each well into an EP tube, centrifuge to discard the supernatant, and save the cell pellet; then add cell lysis buffer to the EP tube and lyse on ice for 30 minutes.
  • the results are shown in Figure 6.
  • the results show that the short peptide can significantly improve the symptoms of rabbit ear acne, the swelling of rabbit ears, the disappearance of epidermal keratinization and acne, the reduction of sebaceous gland hyperplasia, and the gradual recovery of pores. It can be seen that the short peptide has an effect on rabbit ear acne. Significant repair effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation d'un peptide court à petites molécules dans la préparation de produits destinés à traiter l'acné. Le peptide court à petites molécules selon la présente invention est un peptide court dérivé du bFGF et dégradable composé de 8 résidus d'acides aminés, et sa séquence d'acides aminés est LQLQAEER. Le peptide court à petites molécules peut inhiber la prolifération excessive des glandes sébacées et réduire la sécrétion de sébum de la peau, présente une grande stabilité, une faible toxicité et peu d'effets secondaires. Il est approprié pour un large éventail de personnes, présente une bonne perméabilité cutanée, peut continuer à agir sur un site à traiter, et peut par conséquent être utilisé pour lutter contre l'acné, en particulier pour le traitement de l'acné provoquée par des changements de niveaux hormonaux pendant l'adolescence et la grossesse.
PCT/CN2021/078441 2020-03-06 2021-03-01 Utilisation d'un peptide court à petites molécules dans la préparation d'un produit destiné à traiter l'acné WO2021175186A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010151278.4 2020-03-06
CN202010151278.4A CN111249440A (zh) 2020-03-06 2020-03-06 小分子短肽在制备治疗痤疮的产品中的应用

Publications (1)

Publication Number Publication Date
WO2021175186A1 true WO2021175186A1 (fr) 2021-09-10

Family

ID=70952885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/078441 WO2021175186A1 (fr) 2020-03-06 2021-03-01 Utilisation d'un peptide court à petites molécules dans la préparation d'un produit destiné à traiter l'acné

Country Status (2)

Country Link
CN (1) CN111249440A (fr)
WO (1) WO2021175186A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114573661A (zh) * 2022-04-27 2022-06-03 冯来坤 一种小分子肽及在促进生物大分子透皮吸收中的用途
WO2023186193A1 (fr) 2022-03-31 2023-10-05 Contipro A.S. Hexapeptide, composition comprenant celui-ci et son utilisation topique

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249440A (zh) * 2020-03-06 2020-06-09 暨南大学 小分子短肽在制备治疗痤疮的产品中的应用
CN114681588B (zh) * 2022-02-17 2023-06-06 中山大学 多肽en-9在制备治疗痤疮的产品中的应用
CN116425836B (zh) * 2022-12-16 2024-04-16 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) A+多肽/蛋白质及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296940A (zh) * 2005-10-24 2008-10-29 凯尔杰有限公司 具有改善皮肤状态或治疗牙周疾病功效的肽
US20110319295A1 (en) * 2007-11-06 2011-12-29 Jamieson Jr Gordon A MASS SPECTROMETRY ASSAY FOR eIF4E AND eIF4E REGULON ACTIVITY
CN104356204A (zh) * 2014-11-17 2015-02-18 暨南大学 一种抗肿瘤小分子多肽及应用
US20150323545A1 (en) * 2011-12-21 2015-11-12 Integrated Diagnostics, Inc. Selected reaction monitoring assays
CN111253469A (zh) * 2020-03-06 2020-06-09 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
CN111249440A (zh) * 2020-03-06 2020-06-09 暨南大学 小分子短肽在制备治疗痤疮的产品中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988262B (zh) * 2012-12-20 2014-08-20 中国科学院南海海洋研究所 一种具有祛痘功效的蜂毒组合物
CN105726459B (zh) * 2016-02-17 2019-05-10 北京乳凝创智生物技术研发中心（有限合伙） 多肽螯合钙在经皮吸收制剂制备中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296940A (zh) * 2005-10-24 2008-10-29 凯尔杰有限公司 具有改善皮肤状态或治疗牙周疾病功效的肽
US20110319295A1 (en) * 2007-11-06 2011-12-29 Jamieson Jr Gordon A MASS SPECTROMETRY ASSAY FOR eIF4E AND eIF4E REGULON ACTIVITY
US20150323545A1 (en) * 2011-12-21 2015-11-12 Integrated Diagnostics, Inc. Selected reaction monitoring assays
CN104356204A (zh) * 2014-11-17 2015-02-18 暨南大学 一种抗肿瘤小分子多肽及应用
CN111253469A (zh) * 2020-03-06 2020-06-09 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
CN111249440A (zh) * 2020-03-06 2020-06-09 暨南大学 小分子短肽在制备治疗痤疮的产品中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BODO MELNIK, GERD SCHMITZ: "FGFR2 signaling and the pathogenesis of acne", JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, vol. 6, no. 9, 1 January 2008 (2008-01-01), pages 721 - 728, XP055842088 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186193A1 (fr) 2022-03-31 2023-10-05 Contipro A.S. Hexapeptide, composition comprenant celui-ci et son utilisation topique
CN114573661A (zh) * 2022-04-27 2022-06-03 冯来坤 一种小分子肽及在促进生物大分子透皮吸收中的用途
CN114573661B (zh) * 2022-04-27 2023-10-27 冯来坤 一种小分子肽及在促进生物大分子透皮吸收中的用途

Also Published As

Publication number Publication date
CN111249440A (zh) 2020-06-09

Similar Documents

Publication Publication Date Title
WO2021175186A1 (fr) Utilisation d'un peptide court à petites molécules dans la préparation d'un produit destiné à traiter l'acné
AU2018260917B2 (en) Methods and compositions of bile acids and salts for reduction of fat
ES2829637T3 (es) 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné
JP2020529980A (ja) 皮膚の弛緩と身体の輪郭を改善するための組成物および方法
CN111253469B (zh) 一种自组装短肽及其在治疗痤疮方面的应用
KR20030009454A (ko) 진세노사이드Ｒｂ1으로 된 피부조직 재생촉진제
BR112012001491B1 (pt) Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica
CN101820765A (zh) 包含雄激素受体降解(ard)增强剂的组合物和预防性或治疗性治疗皮肤病与脱发的方法
Li et al. Evaluation of efficacy of aloin in treating acute trauma in vitro and in vivo
CN105611919A (zh) 包含胆汁酸-脂肪酸缀合物的抗痤疮组合物
WO2024125641A1 (fr) Série de polypeptides/protéines et leurs utilisations
US20240082134A1 (en) Compositions and methods of use for treatment or improvement of the condition and appearance of skin
JP2002212100A (ja) ニキビ予防及び治療用スフィンゴ脂質組成物
US20200069750A1 (en) Extracts from arthrospira and uses thereof
KR100593707B1 (ko) 피부 표면에 도포 되어 항균 및 과잉 피지 분비 억제작용에 의해 여드름성 피부, 지루성 피부 등의 개선에도움을 주는 화장료 조성물 및 그의 제조 방법
WO2018120401A1 (fr) Composition cosmétique
EP2070531B1 (fr) Préparation pharmaceutique contenant des antagonistes de récepteur H2 d'histamine ayant une activité cicatrisante à faibles doses
JP6368219B2 (ja) エストロゲン受容体β活性化剤
Nie et al. Thyrotropin-releasing hormone and its analogs accelerate wound healing
da Rocha et al. The efficacy of an oral probiotic associated with a fixed combination of benzoyl peroxide and adapalene in the treatment of acne: a randomized, double-blind, placebo-controlled clinical trial.
ITMI20132157A1 (it) Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
Lestari et al. A rare case of porokeratosis mibelli in 3-year-old boy
JP2023546530A (ja) 線維症の処置および創傷治癒の方法
Saleh Sequential peeling as a monotherapy for treatment of milder forms of acne vulgaris

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21763736

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21763736

Country of ref document: EP

Kind code of ref document: A1